Held by 4 specialist biotech funds
High Convergence# Signal Note: RTW Investments Initiates $17.7M Position in Cullinan Therapeutics Wong's entry into CGEM signals confidence in Cullinan's clinical pipeline, likely driven by upcoming data catalysts in its lead programs—CT-388 (EGFR exon 20 insertion NSCLC) and CT-046 (DLL3 lung cancer).
AI analyst context — unlock full analysis
# Signal Note: OrbiMed Initiates CGEM Position OrbiMed's new $2.8M stake in Cullinan signals conviction in the company's pipeline, likely driven by near-term catalysts in its lead programs: CT-388 (a menin inhibitor for acute leukemia showing early promise) and CT-707 (targeting KRAS mutations in solid tumors). The timing suggests positioning ahead of potential clinical readouts or regulatory milestones, though specific catalysts warrant confirmation via company filings and upcoming conference presentations.
+ 2 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial